Transgenic Expression of a Human Polyreactive Ig Expressed in Chronic Lymphocytic
T he elimination of B cells expressing Ig with self-reactivity is critical for establishing and maintaining immunological self-tolerance. Most autoreactive B cells are deleted or rendered anergic at the immature stages in the marrow, as has been clearly demonstrated in studies of Ig transgenic mice (1) (2) (3) (4) (5) . Autoreactive, nonanergic B cells that escape the marrow generally are eliminated upon encounter with autoantigen in the periphery (6 -8) .
Although anergy is the primary mechanism of tolerance to soluble self-Ags in the periphery, a notable exception is tolerance to self-IgG. High-affinity rheumatoid factor (RF) 3 -expressing B cells can be deleted by activation-induced apoptosis upon encounter with soluble human (h)IgG (9, 10) . In contrast, B cells expressing Ig with low affinity for self-IgG are apparently unaffected by the presence of autoantigen (11) . Many such Abs are also polyreactive, because they bind with low affinity to two or more distinct self-Ags. Unlike the pathologic high-affinity RF found in patients with rheumatoid arthritis, these natural autoantibodies are present in the circulation of many normal healthy individuals where they have no apparent pathological significance. However, similar Abs are also frequently associated with graft-vs-host disease (GVHD), mixed cryoglobulinemia, or Waldenströms macroglobulinemia, and are expressed by the malignant B cells of patients with various lymphoproliferative diseases, such as chronic lymphocytic leukemia (CLL) (12) . The link between Ab specificity and these disease processes is unclear.
Polyreactive autoantibodies are naturally occurring Ig, primarily of the IgM isotype, that bind with low affinity to two or more distinct self-or nonself-Ags, such as hIgG, ssDNA, dsDNA, histones, cardiolipin, actin, and/or cytoskeletal components (13, 14) . The autoreactive B cells that produce these Ig are not rendered anergic, because the autoantibodies they produce constitute a large fraction of total serum Ig. Such Abs additionally account for a large proportion of the early human B cell repertoire and are speculated to contribute to homeostasis and/or competence of the primary humoral immune response. Polyreactive autoantibodies generally are encoded by nonmutated germline V region genes (V genes). In both humans and mice, the cells that frequently produce these autoantibodies are B-1 B cells that coexpress B cell surface Ags and the CD5 molecule. In mice, these cells are commonly found in the peritoneum (15, 16) .
Mounting evidence exists from several recent studies that engagement of the B cell receptor (BCR) with self-or autoantigen can influence the fate and differentiation of B cells in lymphoid tissues (17) (18) (19) (20) (21) (22) . Antigenic selection also has been suggested for the development and maintenance of natural autoantibodies (13, 14, 20, 23) . This is supported by studies showing that such polyreactive Ig are encoded by a limited and conserved set of Ig V H genes (24) . Also, structure-function analyses of Ig H chains have demonstrated that the somatically generated third complementarity determining region contributes significantly to the polyreactive binding activity of natural autoantibodies (25) (26) (27) . Several of the latter studies were conducted with polyreactive Ig isolated from leukemic B cells of patients with CLL, a disease in which there is frequent neoplastic B cell expression of polyreactive IgM autoantibodies, such as those that bind IgG, cardiolipin, ssDNA, actin, and/or thyroglobulin (12, 28) . How cells expressing polyreactive or natural autoantibodies are regulated or are able to evade immune tolerance is not known. Neither is it clear why such Abs are disproportionately represented in CLL, mixed cryoglobulinemia, Waldenström's macroglobulinemia, or during GVHD following allogenic stem cell transplantation.
To study this, we generated transgenic mice with B cells that express a hIgM/ Ab with low-affinity RF activity (23) . This Ab was derived from a patient with CLL (designated SMI), whose H and L chain genes were encoded by 51p1 and A27, respectively. This Ab also binds myoglobin, thyroglobulin, actin, and ssDNA. The SMI mice were compared with transgenic mice, designated AB29, that have B cells that express a hIgM/ RF with high affinity for hIgG, but without reactivity with other known Ags, and in this case, represent a negative control (29) . We demonstrated that SMI hIgM/-expressing B cells were neither deleted nor rendered anergic, but populated distinct lymphoid compartments, were responsive to BCR ligation or to nonspecific T cell help, and displayed the phenotype of Ag-experienced, or memory-type B cells.
Materials and Methods

Transgenic mice
Transgenic mice were generated that expressed the genes encoding a polyreactive hIgM/ RF isolated from the leukemia B cells of a patient with CLL. The V regions of the H and L chains of SMI, respectively, are encoded by an unmutated allele of the V H 1-69 gene, designated 51p1, and an unmutated VIII gene, designated A27 (23) . The vectors containing human Ig constant regions are those previously described for the generation of the AB29 mice that express the rearranged Ig H and L chains encoding the LES hIgM/ RF, and include the murine H chain enhancer for B cellspecific expression (29) . The S12 and S6 transgenic lines were generated from individual founder mice expressing identical H and L chain genes encoding the SMI polyreactive IgM Ab. Data from experiments using S12 mice are shown, although numerous experiments have been repeated using both strains. All transgenic lines were maintained by backcrossing heterozygous males with C57BL/6 females (The Jackson Laboratory, Bar Harbor, ME). Positive progeny are identified at 4 -5 wk of age by testing sera for the presence of hIgM and human L chains, as previously described (29) . All mice were housed in the animal facility of the University of California, San Diego.
Flow cytometry analyses
Harvested mouse spleens were teased into single-cell suspensions using RP-10 medium (RPMI 1640 medium supplemented with penicillin, streptomycin, 2 mM L-glutamine, 5 ϫ 10 Ϫ5 M 2-ME, and 10% heat-inactivated FBS). Peritoneal cells were harvested before splenectomy by injecting the peritoneum of each mouse with 3 ml of RP-10 medium followed by withdrawal of the peritoneal exudate. Single-cell suspensions were purged of RBCs by hypotonic lysis with ACK lysis solution (BioWhittaker, Walkersville, MD). Washed spleen cells were incubated for 10 min at 4°C with anti-CD16/32 (2.4G2) to block FcR-mediated cytophilic binding (BD PharMingen, San Diego, CA). Cells were stained on ice for 20 min with optimized amounts of the appropriate mAbs conjugated to FITC, PE, PerCP, allophycocyanin, or biotin; washed; and, when necessary, stained for an additional 20 min with streptavidin-allophycocyanin (BD PharMingen). Cells were examined by four-color, multiparameter flow cytometry using a dual-laser FACSCalibur (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo analysis software (Tree Star, San Carlos, CA). Viable lymphocytes were defined by exclusion of propidium iodide and light scatter characteristics. mAbs used included B220 (RA3-6B2), CD23 (B3B4), CD43 (S7), CD21 (7G6), CD5 (53-7. 3), heat-stable Ag (HSA; M1/69), CD3 (17A2), hIgM (G20-127), h (G20-193), and mouse (m)IgM (R6-60.2). These mAbs were purchased from BD PharMingen. The G6 anti-idiotypic mAb was as described (30) .
Immunohistochemistry
Spleens were snap frozen in optimal temperature medium (OCT; Miles Laboratories, Naperville, IL). Five-micrometer sections were prepared from tissue blocks. After air-drying and acetone fixation, endogenous peroxidase activity was blocked using 0.03% hydrogen peroxide. Slides were blocked with 10% goat serum/1% BSA in PBS (pH 7.4) and then stained first for mouse T cells using biotinylated anti-CD3⑀ (BD PharMingen), followed by HRP-streptavidin (Jackson ImmunoResearch, West Grove, PA), and diaminobenzidine substrate (DAKO, Carpinteria CA). Human IgM-expressing cells were detected by sequential addition of alkaline phosphatase-conjugated anti-hIgM (Southern Biotechnology Associates, Birmingham, AL), followed by Vector Blue (Vector Laboratories, Burlingame, CA).
B cell proliferation assays
Freshly harvested splenocytes were washed, counted, and then suspended at 3.5 ϫ 10 6 cells/ml in RP-10 medium. We added 100 l of this cell suspension to each well of a 96-well round-bottom plate. To each well, we added another 100 l of RP-10 medium containing either F(abЈ) 2 goat anti-hIgM (Jackson ImmunoResearch), aggregated hIgG, or LPS (Salmonella minnesota; Sigma-Aldrich, St. Louis, MO), as indicated in the text. Aggregated hIgG was prepared by incubating a solution of IgG at 10 -20 mg/ml in PBS (pH 7.4) at 63°C for 1 h followed by cooling on ice for 2 h. All tests were performed in triplicate. Proliferation was measured on day 2 or 3 of culture by adding 1 Ci of [ 3 H]thymidine to each well. The assay was terminated 18 h later by harvesting plates using an automated cell harvester.
Injection of deaggregated hIgG or G6 anti-Id mAb
Human IgG (Miles Laboratories) was purified using a protein A-Sepharose column, as described (29) . The G6 mAb reactive with Ig encoded by the 51p1 V H gene was prepared from the ascites fluid of SCID mice (The Jackson Laboratory) injected with the G6 hybridoma. G6 mAb was partially purified by a 50% ammonium sulfate precipitation, followed by protein A purification and repeated dialyzes into PBS. All preparations of hIgG and G6 mAb were tested by the Limulus amebocyte lysate assay (Associates of Cape Cod, Falmouth, MA) and found to contain Ͻ0.2 ng of endotoxin for each milligram of protein. Aggregated hIgG or G6 were removed from the preparations immediately before injection by ultracentrifugation at 40,000 rpm for 150 min at 4°C using an SW60 rotor. The top 25% of the preparation was removed gently and then diluted in cold PBS to achieve a final Ig protein concentration of 3-4 mg/ml. Immediately thereafter, 2 mg of the deaggregated hIgG or G6 was injected into the peritoneum of each recipient mouse. All mice were sacrificed 7 days later, and the spleen cells were removed for immune phenotypic analyses.
Induction of hIgM secretion in vitro
Spleen cells were added to 96-well round-bottom plates at 3.5 ϫ 10 5 cells/ well in 100-l volume. We then added either medium or hIgG or aggregated hIgG to a final concentration of 10 or 0.5 g/ml, respectively. To determine whether T cell help alone was sufficient to stimulate secretion of hIgM, C57BL/6 bm12 allogenic spleen cells were used as a source of T cells, as described previously (9) . Briefly, 5 ϫ 10 5 SMI, AB29, or nontransgenic littermate spleen cells were added to 96-well flat-bottom plates followed by 5 ϫ 10 5 C57BL/6 bm12 allogenic spleen cells or 5 ϫ 10 5 C57BL/6 control filler spleen cells per well in a total volume of 200 l. All cultures were performed in duplicate wells and using duplicate plates, and incubated at 37°C in 5% CO 2 . One set of plates was used for measuring hIgM-secreting cells by ELISPOT after 4 days of culture. Supernatants were harvested from the other plate after 7 days of culture to determine levels of hIgM in the culture supernatant by ELISA (29) .
Measurement of hIgM-secreting cells by ELISPOT and ELISA
The numbers of hIgM-secreting cells were measured by ELISPOT. Briefly, 96-well flat-bottom microtiter plates were incubated overnight at 4°C with goat anti-hIgM at 10 g/ml in PBS. After washing, the plates were washed with PBS containing 1% BSA to block nonspecific protein-binding sites. Cultured spleen cells were washed to remove secreted hIgM, suspended in fresh RP-10, and then added at various concentrations to the ELISPOT plates. After incubation at 37°C for 4 h, Ab-producing cells were detected using sequential addition of goat anti-hIgM-biotin (Accurate Chemical, Westbury, NY) and streptavidin-alkaline phosphatase (Kirkegaard & Perry Laboratories, Gaithersburg, MD) diluted in PBS followed by 5-bromo-4-chloro-3-indolyl phosphate substrate (Sigma-Aldrich). After developing the plates, the wells containing 5-100 spots were counted. The mean numbers of spots per 10 6 hIgM ϩ cells were calculated from the percentage of hIgM ϩ cells at the initiation of the spleen cell cultures.
Results
Generation and characterization of SMI transgenic mice
We generated transgenic mice (designated SMI) that expressed a hIgM/ polyreactive, low-affinity RF derived from the leukemic B cells of a patient with CLL (23). These animals were compared with control transgenic mice, designated AB29, that expressed a hIgM/ high-affinity RF that reacts with hIgG, but not with other known Ags, including mouse IgG (data not shown) (9, 23, 29, 31) . We found that expression of a low-affinity polyreactive Ab does not lead to cell deletion. Approximately 12% (mean Ϯ SD, 12.0 Ϯ 1.9%; n ϭ 4) of the splenic mononuclear cells of SMI transgenic mice expressed surface (s)hIgM/ at 8 -10 wk of age (Fig. 1A) . The H and L chain Ig transgenes were coordinately expressed on the surface of 32% (31.7 Ϯ 6.0%; n ϭ 4) of the splenic B cells. Furthermore, hIgM/ expression was restricted to B cells (Table I ). Allelic exclusion of the H chain was nearly complete, because cells expressing mIgM did not coexpress hIgM. In some experiments, a small proportion (Ͻ5%) of B cells expressed hIgM in the absence of human , suggesting that L chain allelic exclusion was not absolute. Lastly, we found that SMI splenic B cells expressed levels of sIgM (mean fluorescence intensity ratio, 41.1 Ϯ 3.4) that were significantly lower than that found on AB29 splenic B cells (mean fluorescence intensity ratio, 67.0 Ϯ 3.2; n ϭ 4; p Ͻ 0.0001, Student's t test), consistent with the phenotype of anergic B cells (2) . To examine whether the hIgM/k ϩ B cells of SMI were resistant to deletion, we injected a high-affinity ligand (G6) into the peritoneum of SMI mice. G6, a mouse mAb specific for the crossreactive Id present on the SMI hIgM H chain, does not compete with anti-hIgM mAb for binding to SMI-expressing B cells. Injection of G6 reduced the mean proportion of hIgM/-expressing SMI splenic B cells from 48 to Ͻ3% (Table II) . The reduction of shIgM/-expressing cells was not due to BCR down-modulation, because SMI mice that received deaggregated G6 had a concomitant and corresponding loss of splenic B220 ϩ cells (Table II) . This depletion of hIgM/k ϩ B cells was similar to that noted for AB29 mice injected with deaggregated hIgG. However, SMI animals injected with deaggregated hIgG had negligible loss of transgeneexpressing splenocytes, as did either mouse strain after injection with saline alone (Table II) , demonstrating the significance of the affinity of the Ag-Ab interaction in B cell clearance.
SMI B cells are responsive to ligation of their transgenic BCR
To examine whether SMI hIgM/ B cells were anergic, we examined whether we could induce proliferation of splenic hIgM/-expressing B cells through ligation of the BCR complex. For this, we cultured splenocytes of SMI or AB29 transgenic mice with either F(abЈ) 2 anti-hIgM or aggregated hIgG. F(abЈ) 2 anti-hIgM induced significant proliferation of the hIgM ϩ splenocytes from either SMI (mean Ϯ SD, 90 Ϯ 12 ϫ 10 3 cpm; n ϭ 4) or AB29 (136 Ϯ 45 ϫ 10 3 cpm) (Fig. 2) . However, 10 g/ml aggregated hIgG did not induce significant proliferation of SMI splenocytes (1.4 Ϯ 0.5 ϫ 10 3 cpm), as compared with medium alone (1.2 Ϯ 0.2 ϫ 10 3 cpm). In contrast, the same amount of aggregated hIgG induced proliferation of AB29 splenocytes (26 Ϯ 6 ϫ 10 3 cpm). LPS induced proliferation of splenocytes from SMI, AB29, or nontransgenic mice (data not shown). We conclude that SMI B cells are neither deleted nor rendered anergic in vivo.
SMI splenic B cells are enriched in T1 and marginal zone (MZ) B cell subsets
Human Ig-expressing splenic B cells from SMI mice were examined by flow cytometry for expression of surface Ags that distinguish various defined B cell subsets. We found that the proportion of the hIgM ϩ B cells from 8-to 10-wk-old SMI mice that expressed CD23 (78%) (Fig. 1B, Table III ) was significantly lower than that of hIgM ϩ B cells of age-matched AB29 control mice (97%; n ϭ 4; p Ͻ 0.0001, Student's t test). The subset of B cells (Table III) . Eight-to 10-wk old SMI mice had significantly higher proportions of transgene-expressing splenic T1 B cells (15.3 Ϯ 2.2%) and MZ B cells (6.8 Ϯ 1.8%) than did age-matched AB29 mice, which have only 1.5 Ϯ 0.2% ( p Ͻ 0.0001; n ϭ 4; Student's t test) and 1.3 Ϯ 0.5% ( p Ͻ 0.002; n ϭ 4; Student's t test) T1-type and MZ-type transgeneexpressing splenic B cells, respectively.
SMI peritoneal B cells are enriched in both B-1a and B-1b subsets
We also examined the peritoneal lymphocytes of SMI mice for coexpression of the hIgM transgenes and surface Ags that distinguish various defined B cell subsets. As noted for other mouse strains, the peritoneal B cells of SMI and control AB29 transgenic mice had higher proportions of B-1-type B cells than did the B cells in the spleen (data not shown) (33) . B cells that express hIgM/ constituted 7.2 Ϯ 1.9% or 20 Ϯ 2.0% of the peritoneal lymphocytes from 8-to 10-wk-old SMI or AB29 mice, respectively ( p Ͻ 0.0001; n ϭ 4; Student's t test). However, SMI mice exhibited significantly higher proportions of hIgM/k B-1 B cells in their peritoneum, because 21 Ϯ 4.4% (n ϭ 4) of the peritoneal transgene-expressing B cells from SMI mice were B-1a B cells (CD5 ϩ CD23 Ϫ CD11b ϩ ) (Fig. 3 ) and 4.4 Ϯ 1.2% (n ϭ 4) were B-1b cells (CD5 Ϫ CD23 Ϫ CD11b ϩ ). In contrast, in AB29 mice, only 2.8 Ϯ 1.9% (n ϭ 4) or Ͻ1% (0.7 Ϯ 0.4%; n ϭ 4) of transgene-expressing peritoneal B cells were B-1a-or B-1b-type B cells, respectively. The remaining human transgene-expressing peritoneal B cells were B-2 B cells, as indicated by their coexpression of the CD23 (Fig. 3) .
SMI B cells localize within the periarteriolar sheath (PALS), MZ, and interfollicular space, as well as in the primary follicle
Fresh-frozen sections of spleens from SMI or AB29 control mice were examined to study the tissue distribution of hIgM/-expressing B cells. We found that both strains of mice had transgeneexpressing B cells scattered throughout the primary B cell follicles of the white pulp and mantle zones of secondary follicles, areas where resting mature B cells typically are located (Fig. 4) . However, the SMI mice were distinctive in that many transgene-expressing cells were found to reside within the MZ. In addition, SMI hIgM/-expressing cells also were found in the interfollicular space and PALS, areas typically inhabited by B cells that have encountered Ag. In contrast, AB29 mice had few transgene-expressing B cells in these subanatomic sites.
Age-related changes in transgene expression
We examined for age-related changes in the proportion of transgene-expressing B cells and serum hIgM/ over time. We found the relative proportions of B cells that expressed hIgM/ declined as the mice aged (Table IV) . In addition, the total number of hIgM/ -expressing splenic B cells decreased upon aging from 9 to 45 wk, from 10.8 ϫ 10 6 to 5.4 ϫ 10 6 in SMI mice, and from 14.2 ϫ 10 6 to 9.7 ϫ 10 6 in AB29 mice. In contrast, SMI mice had significantly higher levels of serum hIgM/ than did AB29 mice at any age ( p Ͻ 0.001; Student's t test). For example, at 4 -6 wk of age, the mean serum concentration of hIgM/ was 33 g/ml (32.5 Ϯ 9 g/ml; n ϭ 7) in SMI mice, but only 12 g/ml (12.4 Ϯ 3.1 g/ml; n ϭ 5) in AB29 mice. The differences in the serum concentrations of the transgene IgM/ between the two types of transgenic mice increased as the animals got older. Whereas SMI mice at 30 -32 wk of age had an elevated mean serum concentration of hIgM/ of 55 g/ml (54.7 Ϯ 21.3 g/ml; n ϭ 7), comparably aged AB29 mice showed a decline in mean serum concentration to only 4 g/ml (4.4 Ϯ 1.4 g/ml; n ϭ 5).
SMI B cells secrete Ab in response to T cell help alone
Given the indications that a proportion of the SMI B cells had an Ag-experienced phenotype and the well-documented association of polyreactive autoantibodies with GVHD, we attempted to determine whether T cell help alone is sufficient to stimulate secretion of SMI hIgM, by culturing splenocytes from SMI mice with C57BL/6 bm12 -alloreactive T cells. Addition of C57BL/6 bm12 alloreactive T cells to SMI splenocytes induced differentiation of IgM/ -secreting cells, as assessed by ELISPOT assay on day 4 of culture (2.7 Ϯ 0.7 ϫ 10 3 spots per million B cells; n ϭ 4)) (Fig. 5) . We also noted increased hIgM in the culture supernatants of wells containing the C57BL/6 bm12 -alloreactive T cells by ELISA (data not shown). In contrast, addition of C57BL/6 bm12 -alloreactive T cells to AB29 splenocytes generated significantly fewer IgM/-secreting cells per million B cells (173 Ϯ 50; n ϭ 4; p Ͻ 0.001, Student's t test). All animals had negligible responses to either medium alone or to control autologous C57BL/6 splenocytes (Fig.  5 ). AB29 splenocytes, but not SMI splenocytes, also responded to aggregated hIgG (4.8 Ϯ 0.3 ϫ 10 3 vs 48 Ϯ 55; n ϭ 4).
Discussion
In this study, we found that expression of human low-affinity, polyreactive Ig, encoded by unmutated Ig V genes that are used frequently by CLL B cells, could induce mouse B cells to differentiate into nonnaive, memory-type B cells that are hyperresponsive to nonspecific T cell help. The human Ig-expressing B cells from SMI mice were neither deleted nor rendered anergic, because they were found in the peripheral lymphoid compartments and responded well to stimulation via their transgenic Ag receptors, respectively. Importantly, we found SMI mice, but not control AB29 mice, developed some hIgM/ ϩ B cells in memory-type B cell compartments in the absence of human Ags. Furthermore, SMI mice had significantly higher proportions of hIgM ϩ B cells that were T1-type splenic B cells (CD23 Ϫ CD21 Ϫ HSA high ), A number of other Ig transgenic mice have been used to examine the development and differentiation of B cells, particularly those that express Ag receptors that are reactive against self-Ags. They have demonstrated that differentiation of these B cells is influenced by a combination of mechanisms operating in both the central and peripheral lymphoid compartments (34 -36) . Although BCR expression is critical for B cell differentiation (37, 38) , engagement of the BCR with self-Ag can profoundly influence the fate of B cell development. The ultimate fate of an autoreactive B cell depends upon several factors, such as the form and location of Ag, Ag concentration, structure, the affinity of the expressed BCR, and the availability of T cell helper activity (34, 36) . Mice that are made transgenic for both Ig with high Ag-binding affinity and specific Ag, experience either anergy or deletion of B cells that expressed the Ig transgenes, unless they undergo Ig receptor editing to express BCR that no longer react with the transgenic Ag (39). Unlike transgenics expressing higher affinity receptors for soluble IgG (29) or reacting to membrane-bound hen egg lysozyme (HEL) (3) or H-2 Ags (4), SMI B cells are not deleted and are found in peripheral lymphoid compartments. Additionally, they are not rendered anergic as a consequence of maturational arrest or exclusion from the B cell follicles of the spleen, as are those of other mice such as those specific for dsDNA (40, 41) or sHEL (2, 6, 42) .
The SMI mice share some, but not all, characteristics with other transgenic mice that express Ig with low affinity for self-Ag, such as anti-Sm or anti-ssDNA. The B cells of 2-12H anti-Sm mice, which express a low-affinity Ig specific for an Ag associated with systemic lupus erythematosus, are anergic as a consequence of maturational arrest at the T1 transitional stage of development, and have low levels of transgene in the sera (43) (44) (45) . However, an interesting similarity with SMI is that ϳ30% of the peritoneal B cells of anti-Sm mice are B-1 B cells (44) . B cells expressed by the anti-ssDNA mice were phenotypically mature B-2 cells and were not excluded from B cell follicles, but in contrast to SMI, they were anergic (41, 46) .
Other Ig transgenic mice also have been noted to have an expanded number of transgene-expressing B cells in the MZ. Examples include mice that are transgenic for V H 81x-neonatal-derived Igh (47, 48) , or mice made transgenic for certain autoantibodies (e.g., Ig directed against DNA (1, 49, 50) , phosphorylcholine (51), or nucleoprotein (52)). These findings indicate that transgenic lines with Ig genes derived from diverse sources can have larger MZ B cell compartments, suggesting that this feature is not the result of BCR specificity per se. However, unlike the transgene-expressing B cells of SMI mice, most of these other transgenic mice have loss of allelic exclusion, consistent with the notion that the driving force of MZ B cell development in these animals results from rearrangement and expression of endogenous Ig genes (49, 53) . However, the MZ B cells of SMI mice maintain allelic exclusion, suggesting that the expression of the SMI transgenes is sufficient for MZ B cell development.
Several studies have provided evidence that engagement of the BCR results in positive selection of B cells (17) (18) (19) (20) (21) (22) . Engagement of the BCR is believed to influence the differentiation of a B cell into a particular B cell subset, as well as the peripheral lymphoid compartment in which it resides, and is best demonstrated for the B-1 (18, 54) and MZ (17, 48) B cell lineages. SMI mice have significantly higher percentages of human Ig-expressing peritoneal B cells that express CD5 than do AB29 mice. CD5 is a molecule that modulates BCR signaling, because it acts as a negative regulator in association with Src homology protein-1 phosphatase (55, 56) . It is expressed on the surface of both human and murine B-1 B cells, and on the leukemic B cells of virtually all patients with CLL (57) . Transgenic mice with BCRs characteristic of CD5 ϩ B cells typically develop increased numbers of B-1 B cells, demonstrating the importance of a particular BCR specificity in generating these cells (reviewed in Refs. 58 and 59). If B-1 B cell development requires BCR specificity, then the lack of specific Ag should result in diminished numbers of B-1 B cells in transgenic animals that lack the relevant Ag. Such is the case for transgenic mice that express irrelevant H-2 (54). CD5 can have a direct effect on tolerance induction, because expression of CD5 by anti-HEL B cells was found directly responsible for the reduction or absence of circulating anti-HEL Ab as compared with the large amounts produced by cells lacking CD5 (60) . Therefore, it is possible that, by decreasing the sensitivity of the BCR to activation by Ag, lowaffinity polyreactive B cells such as SMI might avoid tolerance by differentiation to B-1 cells. CLL B cells have been shown to express IgM Abs that display reactivity to self-proteins (27, 61, 62) . In addition to SMI, several other 51p1-encoded Ig expressed in CLL are polyreactive, having reactivity to IgG, cardiolipin, DNA, actin, and thyroglobulin (23, (63) (64) (65) (66) (67) . Several studies have postulated that CLL may arise from a clonal outgrowth of B cells (68, 69) , based on identification of the restricted use of certain D segments and J H genes in 51p1-encoded Ig expressed by CLL B cells encode a third complementarity determining region with conserved amino acid motifs (69) . More recently, a study using microarray analysis revealed that the gene expression pattern of CLL B is distinct from that of other B cell lymphomas or of adult or cord blood B cells (70) . Moreover, this CLL gene expression profile is similar to that of nonnaive, or memory-type, B cells that frequently reside in the MZ of secondary lymphoid tissue. In addition, CLL B cells that have unmutated Ig genes express several genes that are up-regulated during BCR ligation. As such, these leukemia cells in particular appear to have genetic features in common with B cells that have encountered Ag. Although expression of such Ig by normal B cells does not by itself induce the development of CLL, low-level chronic stimulation may result in prolonging the life of an autoreactive B cell and thus provides an expanded window of time in which the requisite events for leukemogenesis can occur. Additionally, because B cells expressing SMI IgM/ are susceptible to nonspecific immune activation by the provision of T cell help alone, such encounter could render them more susceptible than naive or primary B cells to incurring somatic mutations and cytogenetic changes that result in CLL. Conceivably, these cells could be predisposed to leukemogenesis by virtue of their expressed Ig. As such, the Ig expressed by such B cells might be relevant to the etiopathogenesis of CLL, independent of specific human or environmental Ags.
